Testing LY4005130 for non-segmental vitiligo
Part of Skin clinical trials.
This study tests a new medicine called LY4005130 for non-segmental vitiligo, a skin condition where patches lose pigment (color). The trial aims to see if this drug can help restore skin color and stop the spread of white patches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-segmental vitiligo (the type where white patches can appear anywhere on the body) diagnosed at least 3 months ago
- White patches cover 4–60% of your body surface, but not including palms, soles, or top of feet
- You have at least some involvement on your face (at least 0.5% coverage)
- Your vitiligo is either actively spreading or has stabilized (not getting worse and not improving dramatically)
- You have never taken a JAK inhibitor medicine (such as ruxolitinib, tofacitinib, or baricitinib) before, either as a cream or pill
- You do not have serious heart, lung, liver, stomach, or mental health conditions that could make the study unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
This trial tests an oral medication (a tablet) for treating non-segmental vitiligo, a condition where white patches appear on the skin. The goal is to see if the drug can safely help bring color back to those patches.
This Phase 2 trial tests whether a new drug called D-2570 can help restore skin color in people with non-segmental vitiligo (when white patches appear randomly across the body). The study will track how well the drug works and check if it's safe to use.
This study tests a new medicine called FB102 for people with non-segmental vitiligo. It aims to see if the drug is safe and helps restore skin color.
This trial tests a new treatment for non-segmental vitiligo that uses a special liquid made from stem cells, applied through tiny needle pricks or small injections, alongside standard light therapy. It may help restore pigment to white patches with fewer side effects than traditional treatments.
This trial tests a new medicine called GR2301, given as an injection, combined with light therapy, to see if it can help people with vitiligo. It aims to improve skin color in affected areas, especially on the face.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.